- Home
- DSGN vs ARL Comparison
DSGN vs ARL Comparison
Compare DSGN & ARL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- ARL
- Stock Information
- Founded
- DSGN 2017
- ARL 1999
- Country
- DSGN United States
- ARL United States
- Employees
- DSGN N/A
- ARL N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- ARL Building operators
- Sector
- DSGN Health Care
- ARL Real Estate
- Exchange
- DSGN Nasdaq
- ARL Nasdaq
- Market Cap
- DSGN 348.2M
- ARL 231.0M
- IPO Year
- DSGN 2021
- ARL N/A
- Fundamental
- Price
- DSGN $4.02
- ARL $14.43
- Analyst Decision
- DSGN Hold
- ARL
- Analyst Count
- DSGN 3
- ARL 0
- Target Price
- DSGN $7.00
- ARL N/A
- AVG Volume (30 Days)
- DSGN 222.7K
- ARL 5.3K
- Earning Date
- DSGN 11-07-2024
- ARL 11-07-2024
- Dividend Yield
- DSGN N/A
- ARL N/A
- EPS Growth
- DSGN N/A
- ARL N/A
- EPS
- DSGN N/A
- ARL N/A
- Revenue
- DSGN N/A
- ARL $51,029,000.00
- Revenue This Year
- DSGN N/A
- ARL N/A
- Revenue Next Year
- DSGN N/A
- ARL N/A
- P/E Ratio
- DSGN N/A
- ARL N/A
- Revenue Growth
- DSGN N/A
- ARL 0.87
- 52 Week Low
- DSGN $2.25
- ARL $12.51
- 52 Week High
- DSGN $7.77
- ARL $25.96
- Technical
- Relative Strength Index (RSI)
- DSGN 27.98
- ARL 45.27
- Support Level
- DSGN $3.71
- ARL $13.03
- Resistance Level
- DSGN $6.81
- ARL $14.24
- Average True Range (ATR)
- DSGN 0.46
- ARL 0.72
- MACD
- DSGN -0.27
- ARL -0.14
- Stochastic Oscillator
- DSGN 10.00
- ARL 44.53
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About ARL American Realty Investors Inc.
American Realty Investors Inc is a real estate company. The company acquires, develops, and owns income-producing residential and commercial real estate properties. Its segment involves the Residential segment and the Commercial segment. The residential segment is engaged in the acquisition, development, ownership, and management of multifamily properties and the Commercial segment is engaged in the acquisition, ownership, and management of commercial real estate properties. Its holdings include apartments, office buildings, retail centers, and parcels of land.